By Puyaan Singh April 13 (Reuters) - IDEAYA Biosciences and French pharma company Servier said on Monday their combination drug for a type of eye cancer met the main goal of a mid-to-late-stage trial, ...

While immunotherapy is the primary driver of skin sensitivity in melanoma care, Wong issued a "public service announcement" ...

As Skin Cancer Awareness Month approaches this May, SkinScan Ireland and Waterford-based GP Dr David Brennan are encouraging people across Ireland to take a more proactive approach to protecting their ...

A Houma man becomes one of Louisiana’s first to get life‑saving melanoma eye treatment, preserving both his vision and his life.

A closely watched clinical trial testing a new two-drug combination against metastatic uveal melanoma, the deadliest form of ...

A phase 2/3 trial of Ideaya Biosciences and Servier’s eye cancer candidate has hit its primary endpoint, teeing up a filing for accelerated FDA approval in the second half of th ...

At the LSX World Congress in Lisbon this year, web editor Nicole Raleigh spoke with Roi Raz, CEO of ReBio Pharma, a ...

IDEAYA Biosciences (IDYA) stock jumped 26% after its eye cancer drug combo doubled progression-free survival in a Phase 2/3 trial versus standard care.

Servier $210 million bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as the drug has hit the mark in a phase 2/3 that could form the basis of regulatory filings later this ...

How Merck keeps the price of its lifesaving cancer drug, Keytruda, sky-high, locking out patients and squeezing health care ...

Sally Lowe, 31, from Manchester, noticed a black spot and floaters in her vision before being diagnosed with a rare form of ...

In a yearlong investigation led by the International Consortium of Investigative Journalists, reporters from more than 37 ...